Jan 27, 2023 7:00 am EST Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion
Dec 20, 2022 7:00 am EST Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
Dec 16, 2022 7:00 am EST Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Nov 17, 2022 7:00 am EST Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA
Nov 7, 2022 4:35 pm EST Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement
Sep 30, 2022 3:24 pm EDT Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.